We are pleased to announce that Biocytogen will be attending the BioBreakfast Hosted by DelawareBio at the Incyte Corporation! Full of connection and collaboration have the opportunity to discuss ground-breaking research and improved technology in life sciences over a cup of coffee. Join us for an influential breakfast in Delaware!
What is BioBreakfast?
BioBreakfast is the perfect time to meet with over 100 professionals in the New England region about the developments in life sciences, updates in R&D, in addition to networking with key members of the science community. The session will include a presentation by the CEO of Incyte and time to connect with fellow experts.
Event Overview
Date: September 11th, 2025 | Time: 7:30 am
Venue: Incyte Corporation, 1815 Augustine Cut Off, Wilmington, DE 19803
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you in Wilmington!
